Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
China delays mass production of conditional automated vehicles until 2025
25 February 2020IHS Markit Automotive Expert
(Excerpt)
China will delay mass production of conditional automated
vehicles until 2025 from the planned date of 2020, reports Caixin
Global. Conditional driving automation refers to Society of
Automotive Engineers (SAE) Level 3 automated vehicles that are
capable of keeping the lane in highways and designated areas of
motorways. However, they require a human in the driving seat for
lane changes. The development plan was released by the National
Development and Reform Commission (NDRC) and the Ministry of
Industry and Information Technology (MIIT), among several other
government agencies.
Significance: The initial mandate from the
central government aimed to have 50% of all new vehicles sold in
China to have partly autonomous functions by 2020. The delay is due
to the challenges automakers and tech companies are facing to make
autonomous cars safe for public use. However, Chinese cities are
increasingly issuing licences to automakers and technology
companies to test their autonomous vehicle (AV) technology on
public roads. Shanghai has previously issued intelligent connected
vehicle (ICV) demonstration licences to SAIC Motor, BMW, and Didi
Chuxing (DiDi) that allow these companies to use their AVs to
transport qualified passengers (volunteers) as well as goods for
delivery. Wuhan, capital of China's Hubei Province, has granted
commercial licences to Baidu, Shenzhen Haylion Technologies and
DeepBlue Technology to test their autonomous buses.
Read more articles like this one. Get a free trial to AutoIntelligence Daily
The above article is from AutoIntelligence Daily by IHS Markit. Every working day, AutoIntelligence Daily provides about 30 articles focused on automotive news, events and trends. Get a free trial.